The forthcoming Product Liability Directive (PLD) marks a profound shift in the European liability landscape, particularly for pharmaceutical and medical device manufacturers. Among its most consequential innovations is the amended notion of defect introduced under Article 7: a recall, whether that recall stems from safety concerns or from quality related non-compliance, can now be considered when determining the defectiveness of a product. Another important change is the introduction of presumptions regarding defect and/or causality in Article 10.

By allowing courts to consider a recall as an element when determining defectiveness, the Directive effectively intertwines regulatory action with civil liability exposure. For life sciences companies, this creates a new strategic dilemma. Historically, voluntary recalls have been viewed as prudent risk mitigation tools, signals of responsible corporate behavior and a means to limit potential harm. Under the new regime, however, initiating a recall may simultaneously open the door, a bit wider than before, to litigation, class actions, and compensation claims. The ever-present tension between proactive safety management and the risk of triggering legal presumptions will likely become a central consideration in corporate decision making.

Germany is among the first Member States who have already started the legislative process for implementing the PLD. The German bill explicitly says criteria for assessing the defect of a product include "the relevant requirements for product safety, including safety-related cybersecurity requirements," as well as "[p]roduct recalls or other relevant measures by a competent authority, a manufacturer, or any other actor mentioned in §§ 10 to 13 in connection with product safety." An important defence argument is that the PLD itself points out that such interventions should, however, not in themselves create a presumption of defectiveness.

This dynamic becomes more complex when viewed alongside Directive (EU) 2020/1828 on representative actions, which empowers qualified consumer associations to seek injunctive measures compelling companies to implement or expand recall campaigns. In practice, this means that external stakeholders, not only regulators, may influence whether and how a recall proceeds. In Italy, this has become a standard approach for some plaintiffs. A company hesitating to recall a product, notwithstanding the reason for doing so, may find itself pressured to do so through collective redress mechanisms, while simultaneously facing heightened liability once the recall is executed. Applying the rules of the PLD in representative actions under Directive (EU) 2020/1828 may lead to unanticipated complications, as several elements of the PLD do not fit with representative actions of this type.

Together, the PLD and the Directive (EU) 2020/1828 on representative actions create a compliance environment in which product safety, regulatory strategy, and litigation risk are no longer discrete domains, but deeply interconnected. Manufacturers will need to adopt more integrated risk assessment models, ensuring that recall decisions are supported by robust scientific evidence, transparent communication strategies, and coordinated legal oversight. Internal documentation, post market surveillance systems, and crisis response protocols will all require recalibration to withstand scrutiny from regulators, courts, and consumer organizations.

Ultimately, the PLD signals a broader policy trend: the EU's increasing willingness to leverage civil liability and private enforcement as tools for enforcing product safety standards. For the life sciences sector, the challenge will be to navigate this evolving terrain without compromising patient safety or exposing the organization to cascading legal and reputational consequences.